InnoCare begins patient dosing in clinical trial of novel SHP2 allosteric inhibitor ICP 189 in China
By, Admin1 min read
Share
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the first patient has been dosed in clinical trial of the company
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
